Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kezar Life Sciences, Inc. (KZR : NSDQ)

• Company Description    Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $6.29 Daily Weekly Monthly 20 Day Moving Average: 27,587 shares Shares Outstanding: 7.32 (millions) Market Capitalization: $46.06 (millions) Beta: 0.55 52 Week High: $6.93 52 Week Low: $3.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.64% 0.81% 12 Week 42.96% 40.65% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4000 SHORELINE COURT SUITE 300 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-822-5600 fax: - ir@kezarbio.com http://www.kezarlifesciences.com

• General Corporate Information    Officers Christopher Kirk - Chief Executive Officer Graham Cooper - Chairman Marc Belsky - Chief Financial Officer and Secretary Franklin Berger - Director John Fowler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 49372L209 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/24/26 Share - Related Items Shares Outstanding: 7.32 Most Recent Split Date: 10.00 (0.10:1) Beta: 0.55 Market Capitalization: $46.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.37 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/24/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.56 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 44.96% vs. Previous Quarter: 18.18% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -62.53 06/30/25 - -63.51 ROA 12/31/25 - - 09/30/25 - -51.77 06/30/25 - -52.13 Current Ratio 12/31/25 - - 09/30/25 - 7.07 06/30/25 - 7.29 Quick Ratio 12/31/25 - - 09/30/25 - 7.06 06/30/25 - 7.29 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 11.33 06/30/25 - 12.56 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.02 06/30/25 - 0.03 Debt-to-Capital 12/31/25 - - 09/30/25 - 1.63 06/30/25 - 2.78

Powered by Zacks Investment Research ©